Synapticure has secured a $25 million Series A funding round to scale its virtual care platform for neurodegenerative diseases nationwide, according to the company’s press release and confirmed by MobiHealthNews.
Funding and Purpose
The Series A round was led by B Capital and included participation from CommonSpirit Health, CVS Health Ventures, RA Capital Management, Nexus NeuroTech Ventures, alongside existing backers such as Google Ventures, Optum Ventures, and Rock Health Capital, as reported by Synapticure’s announcement and MobiHealthNews.
The capital will be used to expand partnerships with healthcare payers and providers, enhance its technology platform, accelerate clinical research through enrollment support, and extend access to care across all 50 states, per the press release and MobiHealthNews.
Company Background and Growth
Founded in 2019 by patient and caregiver advocates including Brian Wallach, Synapticure began with a seed round led by Google Ventures in early 2022, focused initially on ALS care. This timeline is detailed in earlier company releases and coverage.
Since then, the company has grown rapidly to deliver virtual care services for conditions such as Alzheimer's, Parkinson’s, Huntington’s disease, ALS, and other neurodegenerative disorders across the U.S.
Significance for Patients and Research
This funding round positions Synapticure to improve access to specialized neurological care, reducing historically long wait times for patients, while also enabling faster patient enrollment in clinical trials via its standardized nationwide virtual infrastructure.
Industry observers note that democratizing access in this way can help address disparities in care availability and accelerate both treatment delivery and research advances.
Conclusion
The $25 million Series A marks a major milestone for Synapticure, empowering the company to broaden its reach and impact in neurodegenerative disease care. Its growth reflects a broader trend in telemedicine innovation—especially for underserved patient populations—and highlights the potential of virtual care models to reshape treatment and research.